Jenna Fontenot

Jenna has represented:

• Cantor Fitzgerald & Co. and the other initial purchasers in connection with a $650 million convertible notes offering by CleanSpark, Inc.
• Cantor Fitzgerald & Co. and the other initial purchasers in connection with a $500 million offering of convertible notes by TeraWulf Inc.
• Calliditas Therapeutics AB in connection with its acquisition by Asahi Kasei Corporation in a $1.1 billion tender offer.
• Cantor Fitzgerald & Co. as dealer manager in connection with a tender offer and consent solicitation by Zura Bio Ltd.
• Quantum-Si Incorporated, in connection with its $75 million at-the-market offering.
• Cantor Fitzgerald & Co. as dealer manager in connection with a tender offer and consent solicitation by Marti Technologies, Inc.
• NewAmsterdam Pharma in its $726 million business combination with Frazier Lifesciences.*
• Evercore and William Blair as lead book-runners in the Nasdaq IPO of MiNK Therapeutics.*
• LanzaTech in its $2.2 billion deSPAC merger.*
• Goldman Sachs, Morgan Stanley and other underwriters in an upsized $201 million follow-on offering by Bicycle Therapeutics.*
• Adit EdTech in a $3.3 billion deSPAC merger with Griid Infrastructure.*
• Selecta Biosciences in a $39 million follow-on offering.*
• Cantor Fitzgerald and RBC as underwriters in a $100 million at-the-market offering and a $30 million follow-on offering for MindMed, Inc.*
• Jefferies and Cowen as underwriters in connection with Quotient Ltd.’s follow-on and at-the-market offerings.*
• Cantor Fitzgerald in connection with Marker Therapeutics’ at-the-market offering.*
• Global Pharmaceutical and other life sciences companies in connection with SEC public reporting and corporate governance matters.

*Matters handled prior to DLA Piper

• Co-author, "Shareholder proposals – the great reset again! (Part 2)," Market Edge, March 4, 2025
• Co-author, "Notice of Exempt Solicitations are under scrutiny," Market Edge, February 18, 2025